[Oncology for the general practioner--update 2007].
Despite intensive efforts are malignant diseases still responsible for most of the deaths occurring in persons of middle age. This article reviews some recent recommendations and new developments in cancer prevention and screening. Moreover it lists the different new therapeutic agents that are now in increasing use in oncological treatments with a special focus on their new side effects potential. Especially the skin toxicity associated with agents targeting the epidermal growth factor receptor (EGFR) is reviewed. Treatment guidelines for chemotherapy-induced emesis, diarrhea and myelosuppression are also discussed. Another topic covered is the follow-up of cancer patients after discharge from the oncologist.
Cathomas
R
R
Departement Innere Medizin, Abteilung Onkologie, Kantonsspital Graubünden, Chur. richard.cathomas@ksgr.ch
D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D042241:Early Diagnosis; D005194:Family Practice; D006801:Humans; D008403:Mass Screening; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D010166:Palliative Care; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D000932:Antiemetics; D000970:Antineoplastic Agents